POET2 – editorial

Czech version

Authors: Eva Račická
Authors‘ workplace: Diabetologická a interní ambulance, MUDr. Račická, s. r. o., Ostrava
Published in: Vnitř Lék 2015; 61(1): 8-9
Category: Editorials

Sources

1. International Diabetes Foundation. Diabetes Atlas. 5th ed. 2011. Dostupné z WWW: <http://www.idf.org/diabetesatlas/5e/the global-burden.Accessed10January2012>.

2. U.K. Prospective Diabetes Study Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21(1): 87–92.

3. Wright A, Burden AC, Paisey RB et al. U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25(2): 330–336.

4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55(6): 1577–1596.

5. Gerstein HC, Bosch J, Dagenais GR et al. Origin Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 2012; 367(4): 319–328.

6. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular event. Diabetes Care 2010; 33(6): 1389–1394.

7. Peyrot M, Barnett AH, Meneghini LF et al. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy Study. Diabet Med 2012; 29(5): 682–689.

8. Horák P. Farmakoekonomika léčby diabetu – trendy u nás. Vnitř Lék 2009; 55(4): 331–340.

9. Kruntorádová K, Suchánková E, Klimeš J et al. Náklady na hypoglykemické stavy u pacientů s diabetes mellitus: cost-of-illness studie. Farmakoekonomika 2012; 6(1): 17–21.

10. Kvapil M, Janíčkova Žďárská D, Suchopár J et al. Registr POET2: Srovnání přímých ročních zdravotnických nákladů na léčbu diabetu 2. typu po zahájení léčby inzulinem NPH nebo inzulinem glargin v kombinaci s perorálními antidiabetiky v České republice. Vnitř Lék 2015; 61(1): 24–32.